Abstract
Aims
Dexmedetomidine (DEX), a highly selective and potent α2-adrenergic receptor agonist, has anti-apoptotic, anti-inflammatory, and anti-oxidative stress effects in diabetes mellitus (DM) rats. The underlying molecular mechanisms and signaling pathways of diabetic cardiomyopathy remain poorly understood. This study aimed to elucidate the effect of DEX on cardiac function in DM rats.
Methods
Eight-week-old male Sprague Dawley rats were divided into three groups: control (n = 5), diabetes (DM, n = 7), and diabetes + DEX (DM + DEX, n = 10). DM was induced via intraperitoneal injection of streptozotocin (70 mg/kg); at 3 days later, DEX (1 µg/kg/h) was administered for 4 weeks. Cardiac function was evaluated using pressure–volume loop analysis and echocardiography. Left ventricular (LV) histological sections were used to analyze the interstitial collagen fraction. Using the LV samples, we performed a western blot analysis to evaluate signaling pathways and autophagic markers.
Results
The DM group had lower body weight and higher blood glucose level and heart weight/body weight ratio than the control group. However, metabolic changes did not differ between the DM and DM + DEX groups. Pressure–volume loop analysis and echocardiography showed impaired cardiac function, evidenced by a decrease in systolic and diastolic function, in both DM groups. DEX treatment in DM rats was associated with increased LV end-systolic pressure, LV contractility, cardiac output, and relaxed LV function compared with that in non-treated DM rats. LC3B and autophagy-related gene (ATG) proteins increased in the hearts of DM rats compared with the hearts of control rats. However, DEX reduced the expression of LC3B and ATG proteins in the hearts of DM rats. Increased p-ERK and decreased p-AKT were reduced in the hearts of DEX-treated DM rats.
Conclusions
DEX reduces cardiac dysfunction and impaired autophagy in DM rats. This study reinforces our understanding of the potential anti-autophagic effect of DEX in patients with diabetic cardiomyopathy.
Similar content being viewed by others
Abbreviations
- DM:
-
Diabetes mellitus
- DCM:
-
Diabetic cardiomyopathy
- LV:
-
Left ventricular
- DEX:
-
Dexmedetomidine
- STZ:
-
Streptozotocin
- ECL:
-
Enhanced chemiluminescence
- ERK:
-
Extracellular signal-regulated kinase
- PV loop:
-
Pressure–volume loop
- HR:
-
Heart rate
- LVESP:
-
LV end-systolic pressure
- dP/dt max :
-
Maximal slope of the systolic pressure increment
- dP/dt min :
-
Maximal slope of the diastolic pressure decrement
- E max :
-
Slope of end-systolic pressure–volume relationship
- SW:
-
Stroke work
- EF:
-
Ejection fraction
- SV:
-
Stroke volume
- CO:
-
Cardiac output
- PRSW:
-
Preload recruitable stroke work
- EDPVR:
-
End-diastolic pressure–volume relationship
- LVEDD:
-
LV end-diastolic dimension
- LVESD:
-
LV end-systolic dimension
- ATG:
-
Autophagy-related gene
- TDI E/E′:
-
Ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity
- E/A :
-
Ratio between early (E)-to-late (A) diastolic mitral inflow
- MAPK:
-
Mitogen-activated protein kinase
References
Varga ZV, Giricz Z, Liaudet L, Hasko G, Ferdinandy P, Pacher P (2015) Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. Biochim Biophys Acta 1852:232–242
Kobayashi S, Liang Q (2015) Autophagy and mitophagy in diabetic cardiomyopathy. Biochim Biophys Acta 1852:252–261
Ouyang C, You J, Xie Z (2014) The interplay between autophagy and apoptosis in the diabetic heart. J Mol Cell Cardiol 71:71–80
Carollo DS, Nossaman BD, Ramadhyani U (2008) Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol 21:457–461
Zeng X, Wang H, Xing X, Wang Q, Li W (2016) Dexmedetomidine protects against transient global cerebral ischemia/reperfusion induced oxidative stress and inflammation in diabetic rats. PLoS One 11:e0151620
Erbatur ME, Sezen SC, Bayraktar AC, Arslan M, Kavutcu M, Aydin ME (2017) Effects of dexmedetomidine on renal tissue after lower limb ischemia reperfusion injury in streptozotocin induced diabetic rats. Libyan J Med 12:1270021
Kip G, Celik A, Bilge M et al (2015) Dexmedetomidine protects from post-myocardial ischaemia reperfusion lung damage in diabetic rats. Libyan J Med 10:27828
Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463–477
Kim I, Rodriguez-Enriquez S, Lemasters JJ (2007) Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys 462:245–253
Nakai A, Yamaguchi O, Takeda T et al (2007) The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat Med 13:619–624
Wang H, Wang J, Qu H et al (2016) In vitro and in vivo inhibition of mTOR by 1,25-dihydroxyvitamin D3 to improve early diabetic nephropathy via the DDIT4/TSC2/mTOR pathway. Endocrine 54:348–359
Xu Z, Sun J, Tong Q et al (2016) The role of ERK1/2 in the development of diabetic cardiomyopathy. Int J Mol Sci 17:2001. https://doi.org/10.3390/ijms17122001
Zhang Y, Wang Y, Yang K et al (2014) BMP4 increases the expression of TRPC and basal [Ca2+]i via the p38MAPK and ERK1/2 pathways independent of BMPRII in PASMCs. PLoS One 9:e112695
Gallagher LE, Williamson LE, Chan EY (2016) Advances in autophagy regulatory mechanisms. Cells 5:24. https://doi.org/10.3390/cells5020024
Sanders RD, Maze M (2007) Alpha2-adrenoceptor agonists. Curr Opin Investig Drugs 8:25–33
Venot M, Weis L, Clec’h C et al (2015) Acute kidney injury in severe sepsis and septic shock in patients with and without diabetes mellitus: a multicenter study. PLoS One 10:e0127411
Arslan M, Comu FM, Kip G et al (2014) Effect of dexmedetomidine on erythrocyte deformability during ischaemia–reperfusion injury of heart in diabetic rats. Bratisl Lek Listy 115:494–497
Riquelme JA, Westermeier F, Hall AR et al (2016) Dexmedetomidine protects the heart against ischemia–reperfusion injury by an endothelial eNOS/NO dependent mechanism. Pharmacol Res 103:318–327
Okada H, Kurita T, Mochizuki T, Morita K, Sato S (2007) The cardioprotective effect of dexmedetomidine on global ischaemia in isolated rat hearts. Resuscitation 74:538–545
Ibacache M, Sanchez G, Pedrozo Z et al (2012) Dexmedetomidine preconditioning activates pro-survival kinases and attenuates regional ischemia/reperfusion injury in rat heart. Biochim Biophys Acta 1822:537–545
Sun Y, Jiang C, Jiang J, Qiu L (2017) Dexmedetomidine protects mice against myocardium ischaemic/reperfusion injury by activating an AMPK/PI3K/Akt/eNOS pathway. Clin Exp Pharmacol Physiol 44:946–953
Behmenburg F, Pickert E, Mathes A et al (2017) The cardioprotective effect of dexmedetomidine in rats is dose-dependent and mediated by BKCa channels. J Cardiovasc Pharmacol 69:228–235
Cheng XY, Gu XY, Gao Q, Zong QF, Li XH, Zhang Y (2016) Effects of dexmedetomidine postconditioning on myocardial ischemia and the role of the PI3K/Akt-dependent signaling pathway in reperfusion injury. Mol Med Rep 14:797–803
Engelhard K, Werner C, Eberspacher E et al (2003) The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-d-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 96:524–531
Ding D, Xu S, Zhang H et al (2018) 3-Methyladenine and dexmedetomidine reverse lipopolysaccharide-induced acute lung injury through the inhibition of inflammation and autophagy. Exp Ther Med 15:3516–3522
Shen M, Wang S, Wen X et al (2017) Dexmedetomidine exerts neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with traumatic brain injury. Biomed Pharmacother 95:885–893
Luo C, Ouyang MW, Fang YY et al (2017) Dexmedetomidine protects mouse brain from ischemia–reperfusion injury via inhibiting neuronal autophagy through up-regulating HIF-1alpha. Front Cell Neurosci 11:197
Martinet W, Knaapen MW, Kockx MM, De Meyer GR (2007) Autophagy in cardiovascular disease. Trends Mol Med 13:482–491
Terman A, Brunk UT (2005) Autophagy in cardiac myocyte homeostasis, aging, and pathology. Cardiovasc Res 68:355–365
Xiao T, Luo J, Wu Z, Li F, Zeng O, Yang J (2016) Effects of hydrogen sulfide on myocardial fibrosis and PI3K/AKT1-regulated autophagy in diabetic rats. Mol Med Rep 13:1765–1773
Kanamori H, Takemura G, Goto K et al (2015) Autophagic adaptations in diabetic cardiomyopathy differ between type 1 and type 2 diabetes. Autophagy 11:1146–1160
Eguchi M, Kim YH, Kang KW et al (2012) Ischemia–reperfusion injury leads to distinct temporal cardiac remodeling in normal versus diabetic mice. PLoS One 7:e30450
Xie Z, Lau K, Eby B et al (2011) Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60:1770–1778
Xu X, Kobayashi S, Chen K et al (2013) Diminished autophagy limits cardiac injury in mouse models of type 1 diabetes. J Biol Chem 288:18077–18092
Javadov S, Jang S, Agostini B (2014) Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmacol Ther 144:202–225
Wang S, Luo M, Zhang Z et al (2016) Zinc deficiency exacerbates while zinc supplement attenuates cardiac hypertrophy in high-fat diet-induced obese mice through modulating p38 MAPK-dependent signaling. Toxicol Lett 258:134–146
Zhang N, Yang Z, Yuan Y et al (2015) Naringenin attenuates pressure overload-induced cardiac hypertrophy. Exp Ther Med 10:2206–2212
Zhang L, Ding WY, Wang ZH et al (2016) Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med 14:109
Fei AH, Wang FC, Wu ZB, Pan SM (2016) Phosphocreatine attenuates angiotensin II-induced cardiac fibrosis in rat cardiomyocytes through modulation of MAPK and NF-kappaB pathway. Eur Rev Med Pharmacol Sci 20:2726–2733
Sager HB, Hulsmans M, Lavine KJ et al (2016) Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ Res 119:853–864
Martinez PF, Bonomo C, Guizoni DM et al (2016) Modulation of MAPK and NF-954;B signaling pathways by antioxidant therapy in skeletal muscle of heart failure rats. Cell Physiol Biochem 39:371–384
Thandavarayan RA, Giridharan VV, Arumugam S et al (2015) Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. PLoS One 10:e0119214
Kehat I, Molkentin JD (2010) Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci 1188:96–102
Mutlak M, Kehat I (2015) Extracellular signal-regulated kinases 1/2 as regulators of cardiac hypertrophy. Front Pharmacol 6:149
Lakshmanan AP, Harima M, Sukumaran V et al (2012) Modulation of AT-1R/AMPK-MAPK cascade plays crucial role for the pathogenesis of diabetic cardiomyopathy in transgenic type 2 diabetic (Spontaneous Diabetic Torii) rats. Biochem Pharmacol 83:653–660
Zhang C, Huang Z, Gu J et al (2015) Fibroblast growth factor 21 protects the heart from apoptosis in a diabetic mouse model via extracellular signal-regulated kinase 1/2-dependent signalling pathway. Diabetologia 58:1937–1948
Ravingerova T, Barancik M, Strniskova M (2003) Mitogen-activated protein kinases: a new therapeutic target in cardiac pathology. Mol Cell Biochem 247:127–138
Gerits N, Kostenko S, Moens U (2007) In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice. Transgenic Res 16:281–314
Perez-Zoghbi JF, Zhu W, Grafe MR, Brambrink AM (2017) Dexmedetomidine-mediated neuroprotection against sevoflurane-induced neurotoxicity extends to several brain regions in neonatal rats. Br J Anaesth 119:506–516
Acknowledgements
This study was supported by the following Grants: the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science, ICT & Future Planning (NRF2014R1A1A3053428).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All animal procedures were approved by the Committee for the Care and Use of Laboratory Animals, Yonsei University College of Medicine (No. 2015–0129), and were performed in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health.
Human and animal rights
This article does not contain any studies with human participants performed by any of the authors. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution.
Informed consent
For this type of study formal consent is not required.
Additional information
Managed by Massimo Porta.
Rights and permissions
About this article
Cite this article
Oh, J.E., Jun, J.H., Hwang, H.J. et al. Dexmedetomidine restores autophagy and cardiac dysfunction in rats with streptozotocin-induced diabetes mellitus. Acta Diabetol 56, 105–114 (2019). https://doi.org/10.1007/s00592-018-1225-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00592-018-1225-9